HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Larson, E. Search for Related Content PubMed Articles by Larson, E.

Galantamine improved cognition and global functioning in vascular dementia or Alzheimer’s disease with cerebrovascular disease

The first 150 words of the full text of this article appear below.

Design
6 month randomised (unclear allocation concealment*), blinded (clinicians and patients),* placebo-controlled trial.

Setting
Canada, Denmark, Finland, France, Germany, Ireland, Israel, The Netherlands, Poland, and the UK.

Patients
592 patients (mean age 75 y, 53% men) who met clinical criteria for probable vascular dementia or possible AD with radiological evidence of cerebrovascular disease. Additional inclusion criteria included a score of 10 to 25 on the Mini-Mental State Examination and 12 on the Alzheimer Disease Assessment Scale Cognitive subscale (ADAS-COG). Exclusion criteria included evidence of neurodegenerative disorders other than AD that might cause or contribute to dementia, and cognitive impairment resulting from cerebral trauma. Follow up was 82% and 77% at 3 and 6 months, respectively.

Intervention
Patients were allocated to receive galantamine, 24 mg/day (n = 396) or placebo (n = 196) once daily for 6 months.

Main outcome measures
Cognitive ability measured by the standard 11 item ADAS-COG (ADAS-COG11) and global functioning measured by the Clinician’s . . . [Full text of this article]

Eric Larson, MD, MPH

University of Washington Medical Center
Seattle, Washington, USA